Aardvark Therapeutics Clinical Trial Data
Aardvark Therapeutics reported exploratory efficacy data from its terminated Phase 3 HERO and open-label extension trials for ARD-101 in Prader-Willi syndrome. The data showed reductions in hunger scores (HQ-CT) during treatment that returned to baseline upon discontinuation, and the FDA has lifted a full clinical hold on the program. The company plans to meet with the FDA to align on a new Phase 3 trial design using a lower dose, with clinical activities expected to resume in 2027.